STOCK TITAN
  1. Home
  2. News
  3. DTIL

Precision BioSciences, Inc. - DTIL STOCK NEWS

Welcome to our dedicated page for Precision BioSciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision BioSciences stock.

Precision BioSciences, Inc., based in Durham, North Carolina, is a pioneering biotechnology company dedicated to enhancing life through advanced genome editing. The company employs its proprietary genome editing platform, ARCUS, to develop innovative product candidates aimed at treating human diseases and offering solutions in food and agriculture.

ARCUS, distinguished by its compact size, enables the delivery of gene edits to a broader range of cells and tissues using both viral and non-viral methods. This versatility makes it a robust tool in Precision BioSciences' mission to address various health conditions and agricultural challenges.

The company has recently made significant strides in its projects, partnering with multiple organizations to expand its research and product development capabilities. These collaborations have been pivotal in propelling forward the potential applications of ARCUS technology.

Precision BioSciences is actively engaged in several cutting-edge projects that underscore its commitment to innovation. The company's financial health is reflected in its consistent investment in research and development, ensuring sustained growth and advancement in its technology.

Latest News:

  • Source: iECURE, Inc.
  • Source: Precision BioSciences, Inc.
  • Source: Precision BioSciences
News

iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Rhea-AI Summary

iECURE, Inc. has received Fast Track designation from the FDA for ECUR-506, an in vivo gene insertion program to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency. The designation helps expedite the review process for therapies addressing unmet medical needs. The company's OTC-HOPE study is open for enrollment in the UK, with sites in the US and Australia to follow, focusing on safety, efficacy, and other endpoints.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
clinical trial fda approval
-
News

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

Rhea-AI Summary

Precision BioSciences, Inc. announced a late-breaking poster presentation at the European Association for Study of the Liver Congress 2024, showcasing preclinical safety data for their clinical candidate PBGENE-HBV for the treatment of chronic hepatitis B. The data supports the progression of the gene editing program towards potential clinical trials and regulatory filings in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
-
News

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Rhea-AI Summary
Precision BioSciences regains control of three gene editing programs from Prevail Therapeutics, showcasing ARCUS platform's potential for gene excision and insertion. The collaboration's conclusion allows Precision to independently develop or seek new partners for these programs, maintaining focus on key clinical priorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.57%
Tags
none
News

iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.

Rhea-AI Summary
iECURE, Inc. receives FDA clearance for ECUR-506 gene editing therapy to treat neonatal onset Ornithine Transcarbamylase deficiency. The therapy will be evaluated in newborn males in the US, UK, and Australia, aiming to provide a mutation-agnostic treatment for liver disorders. The Phase 1/2 trial will assess safety, pharmacokinetics, efficacy, and quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
clinical trial
-
News

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced financial results for 2023, highlighting key achievements such as initiating final IND/CTA enabling studies for PBGENE-HBV, completing licensing agreements with Imugene, TG Therapeutics, and Caribou Biosciences, and completing a $40 million public offering to extend cash runway. The company aims to submit IND and/or CTA for PBGENE-HBV in 2024 and PBGENE-PMM in 2025, advancing gene editing programs and differentiating ARCUS within the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
earnings
-
News

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) will release financial results for Q4 and FY 2023 and give a business update on March 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences earnings
News

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy

Rhea-AI Summary
Precision BioSciences presents promising data at MMTD conference for PBGENE-PMM program targeting m.3243-associated primary mitochondrial myopathy. ARCUS technology demonstrates efficient elimination of mutant mitochondrial DNA while preserving wild-type DNA, leading to improved mitochondrial function. Precision plans to submit CTA and/or IND for PBGENE-PMM in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
clinical trial
-
News

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) announces CTA approval for ECUR-506 in the UK, a gene editing therapy for OTC deficiency, marking a significant milestone in potentially revolutionizing treatment for infants with OTC deficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
clinical trial
-
News

iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506

Rhea-AI Summary
iECURE, Inc. announces approval from the U.K. MHRA to expand the OTC-HOPE study for ECUR-506, an investigational gene editing-based therapy for Ornithine Transcarbamylase deficiency. The study aims to assess safety, tolerability, pharmacokinetics, and efficacy of ECUR-506 in newborn males with OTC deficiency, offering a potential alternative to liver transplants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
News

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announces a public offering of 2,500,000 shares of common stock and warrants, raising $40.0 million. Leading life sciences investors participate in the financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.24%
Tags
offering

FAQ

What is the current stock price of Precision BioSciences (DTIL)?

The current stock price of Precision BioSciences (DTIL) is $4.72 as of December 20, 2024.

What is the market cap of Precision BioSciences (DTIL)?

The market cap of Precision BioSciences (DTIL) is approximately 34.9M.

What does Precision BioSciences, Inc. do?

Precision BioSciences is a biotechnology company that uses its ARCUS genome editing platform to develop treatments for human diseases and provide agricultural solutions.

Where is Precision BioSciences, Inc. located?

The company is based in Durham, North Carolina, United States.

What is ARCUS?

ARCUS is Precision BioSciences' proprietary genome editing platform, known for its small size and ability to deliver gene edits to various cells and tissues.

What are some recent achievements of Precision BioSciences?

The company has advanced its product candidates and formed partnerships to expand its research and development, showcasing the potential of ARCUS technology.

What is the focus of Precision BioSciences' current projects?

The company is focused on developing treatments for human diseases and offering innovative solutions in food and agriculture through its genome editing platform.

How does ARCUS differ from other genome editing tools?

ARCUS is unique due to its relatively small size, which allows it to target a wider range of cells and tissues using both viral and non-viral delivery methods.

Who are some partners of Precision BioSciences?

Precision BioSciences collaborates with organizations like iECURE, Inc. to enhance its research and development capabilities.

What kind of financial strategy does Precision BioSciences employ?

The company consistently invests in research and development to drive growth and technological advancement.

What is the significance of Precision BioSciences' work in agriculture?

The company aims to provide agricultural solutions that can improve food production and sustainability through advanced genome editing.

How does Precision BioSciences contribute to human health?

By developing innovative treatments for various diseases using its ARCUS genome editing platform, Precision BioSciences aims to improve patient outcomes and overall health.

Stock DTIL logo
Precision BioSciences, Inc.

Nasdaq:DTIL

DTIL Rankings

#5066 Ranked by Market Cap
N/A Ranked by Dividends

DTIL Stock Data

34.94M
6.59M
6.58%
44.7%
3.13%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
DURHAM